Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

Trial Profile

Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Evacetrapib (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCELERATE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 16 Nov 2016 Results of effect of evcetrapib on cholesterol efflux capacity presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 28 Sep 2016 This trial was completed in Austria (End date: 12 Oct 2015).
    • 19 Oct 2015 Planned End Date changed from 1 Jul 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top